KR101088922B1 - 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘 - Google Patents

사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘 Download PDF

Info

Publication number
KR101088922B1
KR101088922B1 KR1020057003655A KR20057003655A KR101088922B1 KR 101088922 B1 KR101088922 B1 KR 101088922B1 KR 1020057003655 A KR1020057003655 A KR 1020057003655A KR 20057003655 A KR20057003655 A KR 20057003655A KR 101088922 B1 KR101088922 B1 KR 101088922B1
Authority
KR
South Korea
Prior art keywords
alkyl
compound
aryl
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020057003655A
Other languages
English (en)
Korean (ko)
Other versions
KR20050057120A (ko
Inventor
티모씨 제이. 구찌
카밀 파루치
마이클 피. 드와이어
로날드 제이. 돌
비요어 무필 기리자발라반
알랜 말람스
카르멘 에스. 알바레즈
카티크 엠. 키어티카
조슬린 리베라
틴-야우 찬
빈센트 매디슨
씨어리 오. 피쉬맨
로렌스 더블류. 딜라드
빈 디. 트랜
젠 민 헤
레이 안토니 제임스
행순 박
비디아다 엠. 파라드카
더글라스 월쉬 호브스
Original Assignee
파마코페이아, 엘엘씨.
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파마코페이아, 엘엘씨., 쉐링 코포레이션 filed Critical 파마코페이아, 엘엘씨.
Publication of KR20050057120A publication Critical patent/KR20050057120A/ko
Application granted granted Critical
Publication of KR101088922B1 publication Critical patent/KR101088922B1/ko
Assigned to 머크 샤프 앤드 돔 엘엘씨 reassignment 머크 샤프 앤드 돔 엘엘씨 권리지분의 전부이전등록 Assignors: 머크 샤프 앤드 돔 코포레이션
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020057003655A 2002-09-04 2003-09-03 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘 Expired - Lifetime KR101088922B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40802702P 2002-09-04 2002-09-04
US60/408,027 2002-09-04
US42195902P 2002-10-29 2002-10-29
US60/421,959 2002-10-29
PCT/US2003/027555 WO2004022561A1 (en) 2002-09-04 2003-09-03 Pyrazolopyrimidines as cyclin-dependent kinase inhibitors

Publications (2)

Publication Number Publication Date
KR20050057120A KR20050057120A (ko) 2005-06-16
KR101088922B1 true KR101088922B1 (ko) 2011-12-01

Family

ID=42828922

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057003655A Expired - Lifetime KR101088922B1 (ko) 2002-09-04 2003-09-03 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘

Country Status (13)

Country Link
EP (1) EP1537116B1 (https=)
JP (1) JP4881558B2 (https=)
KR (1) KR101088922B1 (https=)
AT (1) ATE469903T1 (https=)
AU (1) AU2003263071B2 (https=)
BR (1) BRPI0314001B8 (https=)
CA (1) CA2497440C (https=)
DK (1) DK1537116T3 (https=)
IL (1) IL167086A (https=)
MX (1) MXPA05002571A (https=)
NO (1) NO20051647L (https=)
NZ (1) NZ539165A (https=)
WO (1) WO2004022561A1 (https=)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563798B2 (en) * 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7601724B2 (en) * 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
CA2497444C (en) * 2002-09-04 2010-11-30 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP4564485B2 (ja) * 2003-02-28 2010-10-20 帝人ファーマ株式会社 ピラゾロ［１，５−ａ］ピリミジン誘導体
GB0305559D0 (en) * 2003-03-11 2003-04-16 Teijin Ltd Compounds
US20070179161A1 (en) * 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
ES2300672T3 (es) * 2003-04-30 2008-06-16 Merck Patent Gmbh Derivados de cromenona.
MXPA06002618A (es) * 2003-09-09 2006-06-05 Ono Pharmaceutical Co Antagonistas del factor de liberacion de corticotropina (crf) y compuestos heterobiciclicos.
JP2007533749A (ja) * 2004-04-20 2007-11-22 アムゲン インコーポレイティッド アリールスルホンアミドおよびそれに関連する使用方法
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
JP5080970B2 (ja) 2004-06-17 2012-11-21 サイトキネティクス・インコーポレーテッド 心疾患を治療するための置換尿素誘導体
US7667036B2 (en) 2004-08-13 2010-02-23 Teijin Pharma Limited Pyrazolo[1,5-a]pyrimidine derivatives
EP1780212A4 (en) * 2004-08-13 2008-10-22 Teijin Pharma Ltd DERIVATIVE OF PYRAZOLO [1,5-a] PYRIMIDINE
AU2005281704A1 (en) 2004-09-06 2006-03-16 Nycomed Gmbh Novel pyrazolopyrimidines
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
WO2007017678A1 (en) * 2005-08-09 2007-02-15 Eirx Therapeutics Limited Pyrazolo[1,5-a] pyrimidine compounds and pharmaceutical compositions containing them
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2621983A1 (en) 2005-09-09 2007-03-22 Schering Corporation Azafused cyclin dependent kinase inhibitors
CN101321760A (zh) * 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶
US20070082900A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
BRPI0712016A2 (pt) * 2006-05-22 2011-12-27 Schering Corp pirazolo[1,5-a]pirimidinas
CA2660953A1 (en) * 2006-08-18 2008-02-21 Schering Corporation Process for resolving chiral piperidine alcohol and process for synthesis of pyrazolo [1,5-a] pyrimidine derivatives using same
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2007312390B2 (en) 2006-10-19 2013-03-28 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
DE102007032349A1 (de) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
US20110009429A1 (en) * 2008-02-26 2011-01-13 Paul Oakley Heterocyclic compounds as inhibitors of cxcr2
TW200944526A (en) * 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
WO2010080864A1 (en) * 2009-01-12 2010-07-15 Array Biopharma Inc. Piperidine-containing compounds and use thereof
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8591943B2 (en) 2009-04-09 2013-11-26 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US20110071115A1 (en) * 2009-09-11 2011-03-24 Cylene Pharmaceuticals, Inc. Pharmaceutically useful heterocycle-substituted lactams
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US9227971B2 (en) 2010-01-19 2016-01-05 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
WO2011094953A1 (en) * 2010-02-08 2011-08-11 F. Hoffmann-La Roche Ag Compounds for the treatment and prevention of influenza
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
NZ604708A (en) 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
JP6007417B2 (ja) 2011-05-31 2016-10-12 レセプトス エルエルシー 新規ｇｌｐ−１受容体安定剤および調節剤
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
WO2013144532A1 (en) * 2012-03-30 2013-10-03 Astrazeneca Ab 3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US9573954B2 (en) 2012-11-16 2017-02-21 University Health Network Pyrazolopyrimidine compounds
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
CA2896731A1 (en) 2012-12-28 2014-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2014143242A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN109867630A (zh) 2013-06-11 2019-06-11 赛尔基因第二国际有限公司 新型glp-1受体调节剂
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
KR102529049B1 (ko) 2013-08-14 2023-05-08 노파르티스 아게 암의 치료를 위한 조합 요법
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3057955B1 (en) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
DK3077397T3 (da) 2013-12-06 2019-12-16 Vertex Pharma 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
CN106458990B (zh) 2014-04-04 2019-06-07 希洛斯医药品股份有限公司 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
EP3129371B1 (en) * 2014-04-05 2020-07-29 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
PL3152212T3 (pl) 2014-06-05 2020-06-15 Vertex Pharmaceuticals Inc. Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych
LT3157566T (lt) 2014-06-17 2019-08-12 Vertex Pharmaceuticals Incorporated Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
HUE061448T2 (hu) 2014-11-16 2023-07-28 Array Biopharma Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid-hidrogénszulfát kristályos formája
AU2015360364B2 (en) 2014-12-10 2020-04-30 Receptos Llc GLP-1 receptor modulators
SI3262028T1 (sl) 2014-12-17 2022-02-28 Pimco 2664 Limited N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidne in N-(-4hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidne spojine in njihova terapevtska uporaba
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
HK1246645A1 (zh) * 2015-03-27 2018-09-14 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP3347018B1 (en) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
GB201517263D0 (en) * 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
CN108697708A (zh) 2015-10-26 2018-10-23 洛克索肿瘤学股份有限公司 Trk抑制剂抗性癌症中的点突变以及与此相关的方法
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
ES2987474T3 (es) 2016-04-04 2024-11-15 Loxo Oncology Inc Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida
ES2836222T3 (es) 2016-05-18 2021-06-24 Loxo Oncology Inc Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
AU2017311691B2 (en) 2016-08-18 2021-12-02 Vidac Pharma Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN108017641B (zh) * 2016-11-02 2021-01-05 深圳铂立健医药有限公司 吡唑并嘧啶化合物作为pi3k抑制剂及其应用
WO2018082444A1 (zh) * 2016-11-02 2018-05-11 叶宝欢 吡唑并嘧啶化合物作为pi3k抑制剂及其应用
WO2018154133A1 (en) * 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
PL233595B1 (pl) * 2017-05-12 2019-11-29 Celon Pharma Spolka Akcyjna Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK
KR102717819B1 (ko) 2017-07-28 2024-10-14 다케다 야쿠힌 고교 가부시키가이샤 Tyk2 억제제 및 이의 용도
GB201715194D0 (en) 2017-09-20 2017-11-01 Carrick Therapeutics Ltd Compounds and their therapeutic use
USRE50663E1 (en) 2017-10-04 2025-11-18 Bayer Aktiengesellschaft Heterocycle derivatives as pesticides
IL276013B2 (en) 2018-01-17 2024-03-01 Glaxosmithkline Ip Dev Ltd Pi4kiiibeta inhibitors
KR20200131268A (ko) 2018-03-12 2020-11-23 바이엘 악티엔게젤샤프트 해충 방제제로서의 융합된 비시클릭 헤테로시클릭 유도체
AU2019254499A1 (en) 2018-04-20 2020-12-03 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
JP7179161B2 (ja) 2018-09-10 2022-11-28 イーライ リリー アンド カンパニー 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体
AU2019370200B2 (en) * 2018-10-30 2024-12-19 Kronos Bio, Inc. Compounds, compositions, and methods for modulating CDK9 activity
TWI800696B (zh) 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
GB201918541D0 (en) 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
WO2021162944A1 (en) 2020-02-12 2021-08-19 Eli Lilly And Company Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives
TWI810520B (zh) 2020-02-12 2023-08-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物
WO2022187518A1 (en) * 2021-03-03 2022-09-09 Ikena Oncology, Inc. Substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds and their use in treating medical conditions
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
GB202108572D0 (en) * 2021-06-16 2021-07-28 Carrick Therapeutics Ltd Therapeutic compounds and their use
WO2024054602A1 (en) * 2022-09-08 2024-03-14 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
TW202543650A (zh) 2024-03-08 2025-11-16 美商海爾達醫療運營公司 異雙官能化合物及其在治療疾病中之用途
WO2026057043A1 (zh) * 2024-09-14 2026-03-19 正大天晴药业集团股份有限公司 作为cdk抑制剂的三并环化合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050079A1 (fr) 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792533A (fr) * 1971-12-09 1973-06-08 Int Chem & Nuclear Corp Nouvelles pyrazolo (1,5a) pyrimidines et leur procede de preparation
JPS57140870A (en) * 1981-11-09 1982-08-31 Canon Inc Controlling apparatus for concentration of plating solution
JPS6157587A (ja) * 1984-08-29 1986-03-24 Shionogi & Co Ltd 縮合複素環誘導体および抗潰瘍剤
EP0628559B1 (en) * 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
ATE355841T1 (de) * 1997-12-13 2007-03-15 Bristol Myers Squibb Co Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
FR2805160B1 (fr) * 2000-02-23 2002-04-05 Oreal Compositions pour la teinture d'oxydation des fibres keratiniques comprenant un n(2-hydroxybenzene)-carbramate ou un n-(2-hydroxybenzene)-uree et une pyrazolopyrimidine, et procedes de teinture
ATE335737T1 (de) 2000-09-15 2006-09-15 Vertex Pharma Isoxazole und ihre verwendung als erk-inhibitoren
FR2817469B1 (fr) * 2000-12-04 2003-04-18 Oreal Composition de coloration, procede d'obtention et utilisation pour la coloration de fibres keratiniques
CA2497444C (en) * 2002-09-04 2010-11-30 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP2004277337A (ja) * 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd ピラゾロ［１，５−ａ］ピリミジン誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050079A1 (fr) 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)

Also Published As

Publication number Publication date
EP1537116B1 (en) 2010-06-02
ATE469903T1 (de) 2010-06-15
CA2497440A1 (en) 2004-03-18
HK1071756A1 (en) 2005-07-29
EP1537116A1 (en) 2005-06-08
KR20050057120A (ko) 2005-06-16
JP4881558B2 (ja) 2012-02-22
AU2003263071A1 (en) 2004-03-29
CA2497440C (en) 2011-03-22
BRPI0314001B1 (pt) 2018-10-23
AU2003263071B2 (en) 2007-03-15
NO20051647L (no) 2005-06-03
JP2006502163A (ja) 2006-01-19
WO2004022561A1 (en) 2004-03-18
NZ539165A (en) 2008-03-28
IL167086A (en) 2015-01-29
BR0314001A (pt) 2005-07-05
BRPI0314001B8 (pt) 2021-05-25
MXPA05002571A (es) 2005-09-08
DK1537116T3 (da) 2010-09-27

Similar Documents

Publication Publication Date Title
KR101088922B1 (ko) 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
KR101196498B1 (ko) 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘유도체
KR101661405B1 (ko) 사이클린 의존성 키나제 억제제로서의 신규 피라졸로피리미딘 유도체
US7432265B2 (en) Imidazopyrazines as cyclin dependent kinase inhibitors
CN100376580C (zh) 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶
US20080050384A1 (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP2010180234A (ja) サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
US7161003B1 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
KR20050072090A (ko) 사이클린 의존성 키나제 억제제로서의 피라졸로피리딘
MXPA06009245A (en) Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors
HK1071756B (en) Pyrazolopyrimidines suitable for the treatment of cancer diseases
HK1144816A (en) Pyrazolopyrimidines suitable for the treatment of cancer diseases
HK1090926B (en) Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors
HK1072056B (en) Imidazopyrazines as cyclin dependent kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050303

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20050429

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080902

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100930

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20110831

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20111125

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20111125

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20141030

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20141030

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20161028

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20161028

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20170929

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20170929

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20180928

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20180928

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20190924

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20190924

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20210929

Start annual number: 11

End annual number: 11

PC1801 Expiration of term

Termination date: 20240303

Termination category: Expiration of duration